Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note

Astrazeneca stock fell 1.17% on September 29, 2026, underperforming the S&P 500's 0.17% decline. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.17 (down 8.82% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.73, trading at a discount to its industry average of 25.2.